Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit
2024-04-05
抗体药物偶联物
Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Medicovestor, Inc. has been chosen as one of 11 finalists from a competitive pool of over 150 applicants spanning more than 20 countries to showcase its innovative Antibody-Drug Conjugate (ADC) platforms at the inaugural JP Morgan Asset Management: Life Sciences Innovation Summit. The event is scheduled to take place at the renowned Cleveland Clinic in Abu Dhabi on May 14th – 15th, 2024.
Unlike current ADCs, Medicovestor's groundbreaking first-in-class ADC platforms prioritize the "A" (antibody) over the "DC" (drug conjugate), harnessing the intrinsic antitumor activities of the backbone antibody. By synergizing the tumor-killing activities of the payload, Medicovestor's approach is expected to enhance clinical efficacy while reducing toxicities.
"We are thrilled to be selected as a finalist for this prestigious summit," said Dr. Seah Lim, Founder and CEO of Medicovestor. "Our focus on unlocking the full potential of antibodies in ADCs sets us apart. We believe this approach has the power to significantly improve patient outcomes."
The Life Sciences Innovation Summit, hosted by JP Morgan Asset Management, serves as a prestigious platform for leading innovators, investors, and industry experts to explore cutting-edge advancements in healthcare and life sciences. Medicovestor's participation underscores its commitment to advancing the field and fostering collaboration among key stakeholders.
During the summit, Medicovestor aims to share insights into its ADC platform development, preclinical progress, and future prospects. The company also seeks to forge strategic partnerships, secure funding opportunities, and accelerate the advancement of its innovative drug delivery solutions.
In further recognition of its innovative work, Medicovestor is proud to also announce its selection as a finalist to present at the Asia BioPartnering Startup Spotlight on April 25, 2024, in Singapore.
For more information about Medicovestor, Inc. and its novel ADC platforms, please visit www.medicovestor.com.
About Medicovestor, Inc.: Medicovestor, Inc. is a pioneering biotechnology company dedicated to developing advanced drug delivery systems. With a focus on maximizing therapeutic efficacy and minimizing toxicities, Medicovestor's innovative approaches aim to revolutionize cancer treatment and improve patient outcomes.
Contact:
Lin Ong CA
Chief Business Officer
Lin.Ong@Medicovestor.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。